Classifying ultra-high risk smoldering myeloma

被引：0
|
作者：
A J Waxman
R Mick
A L Garfall
A Cohen
D T Vogl
E A Stadtmauer
B M Weiss
机构：
[1] Abramson Cancer Center,Division of Hematology
[2] University of Pennsylvania,Oncology
[3] University of Pennsylvania,Department of Biostatistics and Epidemiology
来源：
Leukemia | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：751 / 753
页数：2
相关论文
共 50 条
  • [21] The Ultra-High Risk Concept-A Review
    Yung, Alison R.
    Nelson, Barnaby
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (01): : 5 - 12
  • [22] An algorithm for classifying neurotransmitter signals from ultra-high sensitivity dynamic PET
    Liu, Heather
    Morris, Evan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [23] Daratumumab for high-risk smoldering multiple myeloma-Are we there yet?
    Lal, Bhavesh Mohan
    Al Hadidi, Samer
    EUROPEAN JOURNAL OF CANCER, 2025, 220
  • [24] Risk Stratification and Treatment in Smoldering Multiple Myeloma
    Lussier, Tyler
    Schoebe, Natalie
    Mai, Sabine
    CELLS, 2022, 11 (01)
  • [25] Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
    Sklavenitis-Pistofidis, Romanos
    Aranha, Michelle P.
    Redd, Robert A.
    Baginska, Joanna
    Haradhvala, Nicholas J.
    Hallisey, Margaret
    Dutta, Ankit K.
    Savell, Alexandra
    Varmeh, Shohreh
    Heilpern-Mallory, Daniel
    Ujwary, Sylvia
    Zavidij, Oksana
    Aguet, Francois
    Su, Nang K.
    Lightbody, Elizabeth D.
    Bustoros, Mark
    Tahnri, Sabrin
    Mouhieddine, Tarek H.
    Wu, Ting
    Flechon, Lea
    Anand, Shankara
    Rosenblatt, Jacalyn M.
    Zonder, Jeffrey
    Vredenburgh, James J.
    Boruchov, Adam
    Bhutani, Manisha
    Usmani, Saad Z.
    Matous, Jeffrey
    Yee, Andrew J.
    Jakubowiak, Andrzej
    Laubach, Jacob
    Manier, Salomon
    Nadeem, Omar
    Richardson, Paul
    Badros, Ashraf Z.
    Mateos, Maria-Victoria
    Trippa, Lorenzo
    Getz, Gad
    Ghobrial, Irene M.
    CANCER CELL, 2022, 40 (11) : 1358 - +
  • [26] Should high risk smoldering myeloma be treated outside a clinical trial: NO COMMENT
    Gertz, Morie A.
    Vaxman, Iuliana
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2565 - 2567
  • [27] SMOLDERING MULTIPLE MYELOMA : THE ROLE OF RISK MODELS IN IDENTIFYING HIGH RISK PATIENTS IN REAL LIFE
    Cocito, F.
    Ferretti, V. V.
    Catalano, M.
    Mangiacavalli, S.
    Cartia, C. S.
    Ganzetti, M.
    Fugazza, E.
    Landini, B.
    Cazzola, M.
    Corso, A.
    HAEMATOLOGICA, 2017, 102 : 134 - 135
  • [28] Identifying neurocognitive risk markers in ultra-high risk individuals
    Harrison, L. K.
    Meki, A.
    Patterson, P.
    Jones, C.
    Skeate, A.
    Birchwood, M.
    EARLY INTERVENTION IN PSYCHIATRY, 2008, 2 : A21 - A21
  • [29] POLYGENIC RISK ASSOCIATION IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS
    Lim, Keane
    Lam, Max
    Liu, Jian-Jun
    Lee, Jimmy
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1256 - 1257
  • [30] An algorithm for classifying neurotransmitter signals from future ultra-high sensitivity dynamic PET
    Liu, Heather
    Morris, Evan D.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2021, 41 (1_SUPPL): : 25 - 26
12345